Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.


Sheba Partners with Rhino Health

Sheba Partners with Rhino Health: Advancing AI, Protecting Privacy

Sheba’s ARC Innovation Center and Rhino Health, developer of a federated computing platform for privacy-preserving artificial intelligence applications, announced a strategic partnership designed to accelerate the development and implementation of AI technologies while safeguarding data privacy. Recognizing the technologies’ potential, the ARC Innovation Center already operates a dedicated AI hub where numerous AI solutions have […]
Read More
Sheba Medical Center in Israel and CAPS Medical explore a new bladder cancer treatment.

Sheba and CAPS Medical Partner to Assess a New Bladder Cancer Treatment 

Non-muscle invasive bladder cancer (NMIBC) develops in the tissue that lines the bladder’s inner surface. NMIBC is characterized by a high recurrence rate of up to 80%, which means that, in most cases, the conventional therapeutic approach does not eliminate the malignancy. Traditionally, NMIBC is treated via transurethral resection of bladder tumor (TURBT), a surgical […]
Read More
Sheba Medical Center offers a minimally invasive procedure for Micra leadless pacemaker

Sheba Has Been Designated an Official Micra Pacemaker Training Center

A pacemaker, also called a cardiac pacing device, is a small apparatus that’s placed (implanted) in the chest to help control the heartbeat by sending electrical pulses. It keeps the heart beating regularly and prevents it from beating too slowly. However, pacemaker implantation involves a complicated surgical procedure.  In 2006, Medtronic made history by being […]
Read More
clinical trial

New Hope for Peritoneal Cancer Patients

Peritoneal cancer is a rare malignancy that develops in the peritoneum, a membrane that lines the walls of the abdominal cavity and rests on the abdominal and pelvic organs. Whether originating from a primary tumor within the peritoneum or a metastatic tumor elsewhere in the body, peritoneal cancer is a terminal disease with a poor […]
Read More
Tips for Better Health

Three Tips for Better Health From Sheba’s Experts

The first step to taking control of your eating habits is simple: prepare your own food. Cooking at home not only gives you the ability to know exactly what goes into your meal, but also has a multitude of additional benefits.  The act of cooking requires skills that many people do not regularly utilize, bringing […]
Read More
Aml remission possible with Zantrene as part of medication regimen.

Zantrene May Promote Long-term Remission in  Acute Myeloid Leukemia Patients, Sheba Study Indicates

Zantrene, also known by its generic name bisantrene dihydrochloride, is an anti-cancer drug used both as a low-dose targeted precision oncology agent as well as a cardio-protective chemotherapy drug. Zantrene was developed by Australian Race Oncology, who, together with Sheba, launched a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML) […]
Read More
Maria’s Story of Adversity

Maria’s Story of Adversity and Hope

After developing a fever, 4-year-old Maria was brought to the hospital in her native Cyprus by her parents, Nikolas and Ioana. Doctors diagnosed her with pneumonia, but after only a few days her condition rapidly deteriorated and they feared for her life.  It became clear that Maria’s survival was dependent on access to an ECMO […]
Read More
Lung Cancer

Study of Human Lymphocyte Antigen Peptides Reveals New Possible Lung Cancer Treatments

Headed by Dr. Michael Peled, researcher and attending physician at Sheba’s Institute for Pulmonary Medicine, and Prof. Arie Admon of the Technion – Israel Institute of Technology, the study involved isolating and analyzing peptides (a short chain of amino acids) found in lung fluid, proving that human lymphocyte (a type of white blood cell) antigen […]
Read More
study provied oral immunotherapy for peanut allergy in children is safe and effective.

Oral Immunotherapy Decreases Allergic Reaction to Peanuts in Children, Sheba Study Finds

The seminal study, published in the Annals of Allergy, Asthma & Immunology, was conducted over the course of two years at Sheba Medical Center and analyzed data from children ranging in age from 1 to 18 years with diagnosed peanut allergies. The study indicates that fixed-dose oral immunotherapy safely reduces sensitivity in children with high-threshold […]
Read More